Skip to main content


1. Horváth G.: A krónikus B vírus hepatitis kezelése. LAM 2008, 18:769-775.
2. Keefe EB et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the
United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-41.
3. Fried MW et al.: HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon
alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428-434.
4. Hou J et al.: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1
year of a randomized double-blind trial. Hepatology 2008,47:447-454.
5. Shermann M et al.: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic,
biochemical and serology outcomes through 96 weeks. Hepatology 2008, 48:99-108.
6. Leung N et al.: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with
chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72-79.
7. Jonas MM et al.: Safety, efficacy and pharmacokinetics of adefovir dipivoxil in children and adolescents
(age 2 to <18 years) with chronic hepatitis B. Hepatology 2008, 47:1863-1871.
8. Tan J et al.: Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure
to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008, 48:391-398.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 281
282 Gastro Update 2009
9. Reijnders JGP, Janssen HLA. (szerk. közl).: Potency of tenofovir in chronic hepatitis B: mono or
combination therapy? J Hepatol. 2008, 48:383-386.
10. Jacobson IM. (szerk. közl).: Combination therapy for chronic hepatitis B: ready for prime time? J Hepatol.
2008, 48:687-691.
11. Hui CK et al.: 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil
monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008, 48:714-720.
12. Sung JJY et al.: Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of
HBeAg-positive chronic hepatitis B. J Hepatol. 2008, 48:728-735.
13. Raimondo G et al.: Statements from the Taormina expert meeting on occult hepatitis B virus infection.
J Hepatol 2008, 49:652-657.
14. Challine D et al.: Efficacy of serologic marker screening inidentifying hepatitis B virus infection in
organ, tissue and cell donors. Gastroenterology 2008, 135:1185-1191.
15. Lavanchy D. (szerk közl.).: Hepatitis b virus transmission in organ, tissue and cell transplantation.
Gastroenterology 2008, 135:1041-1043.
16. Yuen MF és mtsai: HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and
risk of hepatocellular carcinoma. Gastroenterology 2008, 135:1192-1192.
17. Mikaeloff Y et al.: Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood.
Neurology 2009, 72:xxx-xxx.
18. Ness JM, Bale JF. (szerk. közl.).: Hepatitis vaccines and pediatric multpile sclerosis. Does timing or
type matter? Neurology 2009,72:xxx-xxx.
19. Maylin S és mtsai: Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis
C. Gastroenterology 2008,135:821-829.
20. Mangia A et al.: Individualized treatment duration for hepatitis C genotype 1 patients: a randomized
controlled trial. Hepatology 2008, 47:43:50.
21. Lawitz E et al.: Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days
in hepatitis C patients. J Hepatol 2008, 49:163-169.
22. Zeuzem S (szerk. közl): Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis
C patients. J Hepatol 2008, 49:157-159.
23. Pockros P et al.: R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus
RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48:385-397.
24. Zeuzem S et al.: Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with
genotype 1 chronic hepatitis C. Hepatology 2008, 48:407-417.
25. Ferenci P et al.: Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding
to pegylated interferon/ribavirin therapy. Gastroenterology 2008,135:1561-1567.
26. Di Bisceglie AM et al.: Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
N Eng J Med 2008, 359:2429-2441.
27. El-Serag HB et al.: Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a
population-based study of US Veterans. Hepatology 2009,49:116-123.
28. White DL et al.: Hepatitis C infection and the risk of diabetes: a systematic review and meta-analysis.
J Hepatol 2008,49:831-844.
29. Hennes EM et al.: Simlified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008,48:169-176.
30. Choi G, Peters M (szerk közl): The challenge of diagnosing autoimmune hepatitis: less is more.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 282
A máj 283
Hepatology 2008, 48:10-12.
31. Czaja AJ: Performance parameters of the diagnostic scoring systems for autoimmune hepatitis.
Hepatology, 2008,48:1540-1548.
32. Tahiri F et al.: Identification of plasma membrane autoantigens in autoimmune hepatitis type 1using a
proteomics tool. Hepatology 2008, 47:937-948.
33. Al-Chalabi T et al.: Impact of gender on the long-term outcome and survival of patients with autoimmune
hepatitis. J Hepatology 2008, 48:140-147.
34. Cullen SN et al.: High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
J Hepatol 2008, 48:792-800.
35. Lindor KD et al.: Randomized, double-blind controlled rial of high-dose ursodeoxycholic acid (UDCA)
for primary sclerosing cholangitis (PSC). Hepatology 2008, 48:378A.
36. Garcia-Tsao G et al.: Portal hypertension and variceal bleeding-unresolved issues. Summary of an
American Association for the Study of Liver Diseases and European Association for the Study of the
Liver single-topic conference. Hepatology 2008, 47:1764-1772.
37. Qamar AA et al.: Platelet count in not a predictor of the presence or development of gastroesophageal
varices in cirrhosis. Hepatology 2008, 47:153-159.
38. de Franchis R et al.: Esophageal capsule endoscopy for screening and surveillance of esophageal
varices in patients with portal hypertension. Hepatology 2008, 47:1595-1603.
39. Lo GH et al.: Improved survival in patients receiving medical therapy as compared with band ligation
for the prevention of esophageal variceal rebleeding. Hepatology 2008, 48:580-587.
40. Bosch J et al.: Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a
randomized, controlled trial. Hepatology 2008, 47:1604-1614.
41. Parsi MA et al.: Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology
2008, 135:803-807.
42. Zapater P et al.: Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected
patients with cirrhosis. Hepatology 2008, 48:1924-1931.
43. Sanyal AJ et al.: A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for
type 1 hepatorenal syndrome. Gastroenterology 2008, 134:1360-68.
44. Martin-Llahi M et al.: Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal
synndrome: a randomized study. Gastroenterology 2008, 134:1352-1359.
45. Rockey DC.: Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography.
Gastroenterology 2008, 134:8-14.
46. Friedrich-Rust M et al.: Performance of transient elastography for the staging of liver fibrosis: a
meta-analysis. Gastroenterology 2008, 134:960-974.
47. Bosetti C et al.: Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology
2008, 48:137-145.
48. Forner A et al.: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of
the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
49. Livraghi T et al.: Sustained complete response and complications rates after radiofrequency ablation of very
early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008, 47:82-89.
50. Forner A, Bruix J. (Szerk. közl.): Locoregional treatment for hepatocellular carcinoma: from clinical
exploration to robust clinical data, changing standards of care. Hepatology 2008, 47:5-7.